Insulin Lispro Kwikpen U-100 (Insulin Lispro) — Medicare Part D spending
Eli Lilly & Co. · Rank #326 by total Part D spend · CMS data year 2023
Medicare Part D spent $129,467,811 on Insulin Lispro Kwikpen U-100 (Insulin Lispro) in 2023, the #326 drug by total Part D spending out of 3,598 drugs. That worked out to about $11.34 per dosage unit, $198 per claim and $601 per beneficiary, across 654,469 claims for 215,312 beneficiaries. Average spending per dosage unit rose +0.6% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Insulin Lispro Kwikpen U-100 (Insulin Lispro) spending at a glance (2023)
| Metric | Insulin Lispro Kwikpen U-100 (Insulin Lispro) |
|---|---|
| Total Part D spending (2023) | $129,467,811 |
| Total spending (2022) | $122,808,329 |
| Year-over-year change in total spending | +5.4% |
| Average spending per dosage unit (2023) | $11.34 |
| Change in spend per dosage unit (YoY) | +0.6% |
| Avg annual change per dosage unit (2019-2023 CAGR) | -11.0% |
| Average spending per claim (2023) | $198 |
| Average spending per beneficiary (2023) | $601 |
| Total claims (2023) | 654,469 |
| Beneficiaries (2023) | 215,312 |
| Total dosage units (2023) | 11,412,034 |
| Manufacturer(s) | Eli Lilly & Co. |
| National rank by total spend (of 3,598 drugs) | #326 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
2022 vs 2023
| Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total spending | $122,808,329 | $129,467,811 | +5.4% |
| Avg spend per dosage unit | $11.27 | $11.34 | +0.6% |
| Avg spend per claim | $202 | $198 | — |
| Avg spend per beneficiary | $618 | $601 | — |
| Total claims | 607,214 | 654,469 | — |
| Beneficiaries | 198,792 | 215,312 | — |
How Insulin Lispro Kwikpen U-100 compares with nearby drugs
Drugs with total Part D spending closest to Insulin Lispro Kwikpen U-100 (Insulin Lispro):
| Drug (rank) | Total spend 2023 | Per dosage unit | Per-unit YoY |
|---|---|---|---|
| Insulin Lispro Kwikpen U-100 (Insulin Lispro) (this drug, #326) | $129,467,811 | $11.34 | +0.6% |
| Rebif (Interferon Beta-1a/Albumin) (#324) | $131,300,521 | $1,732.74 | +7.7% |
| Isentress (Raltegravir Potassium) (#325) | $130,537,595 | $33.53 | +5.7% |
| Tepezza (Teprotumumab-Trbw) (#327) | $129,065,494 | $16,209.70 | +1.2% |
| Lupron Depot (Leuprolide Acetate) (#328) | $128,884,249 | $5,223.03 | +11.6% |
| Repatha Syringe (Evolocumab) (#329) | $128,112,297 | $287.47 | +8.2% |
Frequently asked questions
How much does Medicare Part D spend on Insulin Lispro Kwikpen U-100?
Medicare Part D spent $129,467,811 on Insulin Lispro Kwikpen U-100 (Insulin Lispro) in 2023 (the latest CMS data year), across 654,469 claims for 215,312 beneficiaries. That ranks #326 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.
What is the average spending per dosage unit for Insulin Lispro Kwikpen U-100?
In 2023, the weighted average Medicare Part D spending per dosage unit for Insulin Lispro Kwikpen U-100 (Insulin Lispro) was $11.34. Compared with 2022 it rose +0.6%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.
Who makes Insulin Lispro Kwikpen U-100?
CMS attributes Insulin Lispro Kwikpen U-100 (Insulin Lispro) to Eli Lilly & Co. in the 2023 Part D spending file. Average spending per claim was $198 and per beneficiary $601.
Is the Insulin Lispro Kwikpen U-100 figure the price I pay?
No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.
Keep exploring
Source & what this means
Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-20